Anaplastic large cell lymphoma · 3 regimens
Cost vs Efficacy · 1 point
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Brentuximab vedotin monotherapy Variant #01 | — | R 56 829 | 21d | ~16.7 mo | — | ~17 | ~R 966 097 PFS proxy · indirect | 1 |
GDP Variant #01 | — | R 4 133 | 21d | — | — | ~6 | ~R 24 796 indirect | — |
DHAP Variant #01 | — | R 2 495 | 28d | — | — | ~2 | ~R 4 991 indirect | — |
3 of 3 regimens shown